Accelerate to discover
Related topics
Download today your IsoPlexis e-book: understanding immune Cell Function In Cancer
Dec 1, 2021
Understanding complex immune-cancer interactions is critical to identifying therapeutic targets, devising novel avenues...
IsoPlexis technology: accelerating decisions in immunotherapy with predictive single-cell response
Nov 25, 2021
The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...
Extensive assessment of Cytokine production on the NovoCyte Penteon flow cytometer
Nov 23, 2021
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
Introducing isoLight system - Automated Cellular Proteomics hub
Nov 4, 2021
The IsoLight is a hub for comprehensive functional profiling of each cell type across a large assay menu of single-cell...
Introducing Cytek NEW 25-Color Immunoprofiling Assay & Kit!
Oct 25, 2021
To unleash the power of the Cytek full spectrum cytometry system, Cytek scientists designed and developed the 25-Color...
Oct 20, 2021
Ionizing radiation approaches are effective but use of radioactive radioisotopic elements have become difficult to...
Duke uses XRAD 225 CX to test radiosensitivity hypothesis
Oct 18, 2021
Image guided radiotherapy in a preclinical setting couldn’t be more useful than the treatment of brain tumors, where...
Curiox webinar: Laminar Wash enables single-cell multiomics and cell hashing
Oct 11, 2021
Professor Mats Bemark’s lab at the University of Gothenburg in Sweden studies how the immune system responds to...
May 18, 2016
With the increasing need for new therapies for cancer, autoimmune disorders and Alzheimer’s disease, monoclonal antibodies are proving very successful due to their high affinity and specificity for their target antigens. In cancer, for example, their first use was as antagonists of oncogenic receptor tyrosine kinases, but today monoclonal antibodies have emerged as vehicles for the targeted delivery of potent chemotherapeutic agents and as powerful tools to manipulate anticancer immune responses. Currently,
more than 30 antibody therapeutics are marketed worldwide. Some analysts predict that, given the rate of current revenue growth and potential new approvals, the global market could reach $58 billion by 2016. In addition, there are hundreds of monoclonal antibody-based biologic drugs in various phases of clinical trials worldwide.
Related technologies: HTP Screening
Get more info
Brand profile
IntelliCyt Corporation's high throughput flow technology is the first to enable screening suspension cells, beads, microbes and mixtures.
More info at:
www.intellicyt.com/
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
